Quantoom Biosciences
Quantoom Biosciences is a Belgium-based biotech that develops proprietary microfluidic and robotics-based RNA production and LNP formulation technologies, selling Ntensify® kits and Ncapsulate® reagents to academic and research customers developing mRNA vaccines and therapeutics.
- Company typePrivate
- Founded2021
- HeadquartersNivelles, Belgium
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Quantoom Biosciences does
Quantoom Biosciences is a Belgium-based, privately held biotechnology company founded in 2021 that develops proprietary RNA production and formulation technologies for mRNA vaccine and therapeutic manufacturing. The company's core platform combines microfluidic and robotics-based automation with its registered Ntensify® product family — Ntensify® mano for research-scale RNA synthesis and Ntensify® micro for compact-scale workflows — and is being extended with Ncapsulate® LNP (lipid nanoparticle) formulation kits that encapsulate RNA for delivery. Together these products form an integrated RNA production-to-formulation workflow aimed at researchers developing next-generation RNA applications and therapeutics, with a particular emphasis on personalized cancer vaccines.
The company operates a hybrid revenue model anchored in hardware sales of its Ntensify® kits and Ncapsulate® LNP kits, supplemented by professional-services revenue from co-development and manufacturing collaborations in personalized mRNA cancer vaccines. Go-to-market is channel-led: a pan-European distribution partnership with Europa Biosite (announced March 2026) drives research-customer reach across Europe, while flagship academic reference-site partnerships — the RNA Innovation Foundry at the University of Western Australia (April 2025) and the University of Arizona Center for Advanced Molecular and Immunological Therapies (February 2026) — function as both validation anchors and co-development partners. The company is headquartered in Nivelles, Belgium, employs 101-250 people, and is led by CEO José Castillo.
Quantoom Biosciences firmographics
Firmographics- Name
- Quantoom Biosciences
- Website
- https://quantoom.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Quantoom Biosciences is a Belgium-based biotech that develops proprietary microfluidic and robotics-based RNA production and LNP formulation technologies, selling Ntensify® kits and Ncapsulate® reagents to academic and research customers developing mRNA vaccines and therapeutics.
- Ownership category
- akta.pro rank
Quantoom Biosciences industry classification
Industry- Product category
- RNA Production Technology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)
- akta.pro secondary industries
- RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
Keywords
Where Quantoom Biosciences is headquartered
LocationHeadquarters
- HQ city
- Nivelles
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
Quantoom Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- RNA Production Technologies: Sale and distribution of Ntensify® mano and Ntensify® micro RNA production technologies to researchers across Europe through distribution partnerships
- LNP Formulation Kits: Sale of Ncapsulate® LNP formulation kits for RNA delivery applications as they become commercially available
- mRNA Vaccine Manufacturing Services: Manufacturing of personalized mRNA cancer vaccines through collaboration with research institutions, utilizing microfluidic and robotics-based automation
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Quantoom Biosciences product offering
Product offeringCore offering
Quantoom Biosciences develops and sells proprietary RNA production platforms (Ntensify® mano and Ntensify® micro) and LNP formulation kits (Ncapsulate®) used by researchers and institutions to produce and formulate RNA for therapeutic and vaccine development. The company also provides mRNA vaccine manufacturing services using microfluidic and robotics-based automation for personalized cancer vaccine programs.
Product overview
Quantoom Biosciences offers a suite of RNA production and formulation technologies. The core products include the Ntensify® mano and Ntensify® micro RNA production platforms, which provide rapid RNA synthesis capabilities for research and therapeutic development. The portfolio is complemented by Ncapsulate® LNP formulation kits, which enable researchers to formulate and encapsulate RNA for delivery applications. Together, these products form an integrated workflow from RNA production to formulation for next-generation RNA therapeutics.
Differentiator
Problem solved
Functional benefit
Brands
- Ntensify® mano: RNA production technology for mano-scale applications
- Ntensify® micro
- Ncapsulate® LNP formulation kits
Products and services
- Ntensify® mano
Companies that use Quantoom Biosciences
Customer profileNamed customers1 record
Segments2 records
Quantoom Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Quantoom Biosciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- Europa BiositecoreStrategic distribution partnership for pan-European distribution of Quantoom's Ntensify® mano and Ntensify® micro RNA production technologies. The agreement expands Europa Biosite's portfolio in the rapidly growing RNA research field and is expected to extend to include Ncapsulate® LNP formulation kits as they become available. The companies aim to make high-quality RNA production and formulation tools more accessible to researchers.
- University of Arizona - Center for Advanced Molecular and Immunological Therapies (CAMI)coreCollaboration to develop a novel personalized cancer vaccine framework using mRNA technology and AI. CAMI scientists identify tumor mutations and use AI algorithms to select neoantigen candidates, while Quantoom creates matching mRNA transcripts and manufactures vaccines using microfluidic and robotics-based automation. Initial testing planned in mouse models for melanoma with potential for individualized cancer treatments.
- University of Western Australia - RNA Innovation FoundryflagshipStrategic partnership making RNA Innovation Foundry the reference site for Quantoom Biosciences in Australia and the first in Oceania. The facility advances RNA-based medicine and biotech innovation, connecting academic research with industry practice. Also houses the Australian Centre for RNA Therapeutics in Cancer. Supported by Therapeutic Innovation Australia funding.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Quantoom Biosciences competitors and assessment
Company assessmentDirect peers
- Aldevron: Aldevron manufactures plasmid DNA, mRNA, and proteins for therapeutic developers, directly comparable to Quantoom's RNA production and LNP-formulation offerings.
- eTheRNA immunotherapies: eTheRNA is a Belgium-based mRNA technology and CDMO player developing RNA therapeutics and delivery platforms, comparable to Quantoom on geography, modality, and service offering.
- Vernal Biosciences: Vernal is an mRNA CDMO offering research- and GMP-grade mRNA manufacturing and LNP formulation, directly overlapping Quantoom's Ntensify®/Ncapsulate® stack.
- TriLink BioTechnologies (Maravai LifeSciences): TriLink is a leading manufacturer of mRNA, oligonucleotides, and plasmid DNA for research and clinical use, and is Quantoom's closest functional peer in nucleic-acid production services and reagents.
- Integrated DNA Technologies (IDT): IDT manufactures synthetic RNA and DNA oligonucleotides and serves RNA researchers with production tools, directly comparable to Quantoom's Ntensify® RNA production platforms.
Broad incumbents
- CureVac: CureVac is an established mRNA therapeutics company with proprietary RNA production technology and manufacturing capability, overlapping with Quantoom on RNA platform and CDMO-style operations.
- GenScript: GenScript provides gene synthesis, RNA services, and cell therapy manufacturing globally, with a broader portfolio but comparable RNA/customer-adjacent offerings to Quantoom.
- BioNTech: BioNTech is a leading mRNA company with large-scale manufacturing and a broad pipeline including personalized cancer vaccines, putting it in adjacent competition with Quantoom's manufacturing-services offering.
- Lonza: Lonza is a global CDMO with established mRNA and lipid nanoparticle manufacturing services, representing the scaled incumbent against which Quantoom's automated RNA platform must compete for commercial customers.
- Moderna: Moderna operates one of the world's largest mRNA manufacturing footprints across vaccines and therapeutics, setting the benchmark for at-scale RNA production against which Quantoom's automation approach must compete.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Quantoom Biosciences social profiles
Digital presenceQuantoom Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quantoom Biosciences leadership team
Management profileNumber of profiles
Quantoom Biosciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quantoom Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quantoom Biosciences
What does Quantoom Biosciences do?
Quantoom Biosciences develops and sells proprietary RNA production platforms (Ntensify® mano and Ntensify® micro) and LNP formulation kits (Ncapsulate®) used by researchers and institutions to produce and formulate RNA for therapeutic and vaccine development. The company also provides mRNA vaccine manufacturing services using microfluidic and robotics-based automation for personalized cancer vaccine programs.
Is Quantoom Biosciences a public or private company?
Quantoom Biosciences is a private company. It is classified as unknown and is currently operating.
When was Quantoom Biosciences founded?
Quantoom Biosciences was founded in 2021. It employs 101 to 250 people.
Where is Quantoom Biosciences based?
Quantoom Biosciences is headquartered in Nivelles, Belgium, in the Europe region.
How does Quantoom Biosciences make money?
Three revenue lines are on record. RNA Production Technologies are the primary driver. The others are LNP Formulation Kits and mRNA Vaccine Manufacturing Services.
Who are Quantoom Biosciences's main competitors?
Direct peers on record are Aldevron, eTheRNA immunotherapies, Vernal Biosciences, TriLink BioTechnologies (Maravai LifeSciences) and Integrated DNA Technologies (IDT). Broad incumbents are CureVac, GenScript, BioNTech, Lonza and Moderna.
Does Quantoom Biosciences have an API?
No public API is recorded for Quantoom Biosciences.
What industry is Quantoom Biosciences in?
Quantoom Biosciences's product category is RNA Production Technology. Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAAADAF, RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC). Its NAICS code is 325414 and its SIC code is 2836.